Compare Solasia Pharma KK with Similar Stocks
Dashboard
1
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -229.10
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -229.10
2
Poor long term growth as Operating profit has grown by an annual rate 12.40% of over the last 5 years
3
Negative results in Jun 26
4
Risky -
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 7,656 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.90
-52.17%
4.48
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2026)
Net Profit:
-272 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.0%
0%
24.0%
6 Months
-3.12%
0%
-3.12%
1 Year
-8.82%
0%
-8.82%
2 Years
-35.42%
0%
-35.42%
3 Years
-31.11%
0%
-31.11%
4 Years
-47.46%
0%
-47.46%
5 Years
-75.4%
0%
-75.4%
Solasia Pharma KK for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.06%
EBIT Growth (5y)
12.40%
EBIT to Interest (avg)
-218.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.23
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.68
EV to EBIT
-5.47
EV to EBITDA
-5.70
EV to Capital Employed
27.94
EV to Sales
11.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-510.59%
ROE (Latest)
-52.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
2.00
24.00
-91.67%
Operating Profit (PBDIT) excl Other Income
-256.00
-232.00
-10.34%
Interest
6.00
19.00
-68.42%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-272.00
-263.00
-3.42%
Operating Profit Margin (Excl OI)
-132,500.00%
-10,041.70%
-12,245.83%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -91.67% vs -60.00% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -3.42% vs 12.33% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
429.00
316.00
35.76%
Operating Profit (PBDIT) excl Other Income
-825.00
-796.00
-3.64%
Interest
14.00
5.00
180.00%
Exceptional Items
0.00
-959.00
100.00%
Consolidate Net Profit
-876.00
-1,941.00
54.87%
Operating Profit Margin (Excl OI)
-2,002.30%
-3,136.10%
113.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 35.76% vs -48.78% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 54.87% vs -74.55% in Dec 2024
About Solasia Pharma KK 
Solasia Pharma KK
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






